Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

the C-TEAM study group and the Taiwan Liver Diseases Consortium

Research output: Contribution to journalArticlepeer-review

106 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients'. Together they form a unique fingerprint.

Medicine & Life Sciences